- Home
- ATAI vs AQST Comparison
ATAI vs AQST Comparison
Compare ATAI & AQST Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | ATAI | AQST |
|---|---|---|
| Founded | 2018 | 2004 |
| Country | Netherlands | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.4B | 809.3M |
| IPO Year | 2021 | 2018 |
Fundamental Metrics
Financial Performance| Metric | ATAI | AQST |
|---|---|---|
| Price | $3.97 | $5.79 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 5 | 6 |
| Target Price | ★ $14.00 | $8.83 |
| AVG Volume (30 Days) | ★ 3.2M | 2.3M |
| Earning Date | 11-12-2025 | 11-05-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | $3,018,000.00 | ★ $43,397,000.00 |
| Revenue This Year | $943.83 | N/A |
| Revenue Next Year | N/A | $52.69 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 811.78 | N/A |
| 52 Week Low | $1.15 | $2.12 |
| 52 Week High | $6.75 | $7.55 |
Technical Indicators
Market Signals| Indicator | ATAI | AQST |
|---|---|---|
| Relative Strength Index (RSI) | 41.30 | 44.66 |
| Support Level | $3.88 | $5.61 |
| Resistance Level | $4.33 | $6.44 |
| Average True Range (ATR) | 0.23 | 0.31 |
| MACD | 0.02 | -0.05 |
| Stochastic Oscillator | 15.82 | 16.00 |
Price Performance
Historical ComparisonAbout ATAI ATAI Life Sciences N.V.
Atai Beckley NV is a clinical-stage biopharmaceutical company. It aims to develop mental health treatments to transform patient outcomes. The company's pipeline of psychedelic-based therapies includes VLS-01 and BPL-003 for the treatment-resistant depression (TRD) and EMP-01 (oral R-MDMA) for social anxiety disorder.
About AQST Aquestive Therapeutics Inc.
Aquestive Therapeutics Inc is a specialty pharmaceutical company engaged in developing and commercializing differentiated products to meet medical needs. Its later-stage product pipeline focuses on the treatment of diseases of the Central Nervous System (CNS), and an earlier-stage pipeline for the treatment of severe allergic reactions, including anaphylaxis. Its commercial product portfolio includes Suboxone, Emylif, Ondif and Sympazan. The product pipeline includes Libervant Buccal Film, AQST-108. The majority of its revenue comes from the United States.